Cargando…

Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios

BACKGROUND: Missense (aminoacid changing) variants found in cancer predisposition genes often create difficulties when clinically interpreting genetic testing results. Although bioinformatics has developed approaches to predicting the impact of these variants, many of these approaches have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Karchin, Rachel, Agarwal, Mukesh, Sali, Andrej, Couch, Fergus, Beattie, Mary S.
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587343/
https://www.ncbi.nlm.nih.gov/pubmed/19043619
_version_ 1782160913579638784
author Karchin, Rachel
Agarwal, Mukesh
Sali, Andrej
Couch, Fergus
Beattie, Mary S.
author_facet Karchin, Rachel
Agarwal, Mukesh
Sali, Andrej
Couch, Fergus
Beattie, Mary S.
author_sort Karchin, Rachel
collection PubMed
description BACKGROUND: Missense (aminoacid changing) variants found in cancer predisposition genes often create difficulties when clinically interpreting genetic testing results. Although bioinformatics has developed approaches to predicting the impact of these variants, many of these approaches have not been readily applicable in the clinical setting. Bioinformatics approaches for predicting the impact of these variants have not yet found their footing in clinical practice because 1) interpreting the medical relevance of predictive scores is difficult; 2) the relationship between bioinformatics “predictors” (sequence conservation, protein structure) and cancer susceptibility is not understood. METHODOLOGY/PRINCIPAL FINDINGS: We present a computational method that produces a probabilistic likelihood ratio predictive of whether a missense variant impairs protein function. We apply the method to a tumor suppressor gene, BRCA2, whose loss of function is important to cancer susceptibility. Protein likelihood ratios are computed for 229 unclassified variants found in individuals from high-risk breast/ovarian cancer families. We map the variants onto a protein structure model, and suggest that a cluster of predicted deleterious variants in the BRCA2 OB1 domain may destabilize BRCA2 and a protein binding partner, the small acidic protein DSS1. We compare our predictions with variant “re-classifications” provided by Myriad Genetics, a biotechnology company that holds the patent on BRCA2 genetic testing in the U.S., and with classifications made by an established medical genetics model [1]. Our approach uses bioinformatics data that is independent of these genetics-based classifications and yet shows significant agreement with them. Preliminary results indicate that our method is less likely to make false positive errors than other bioinformatics methods, which were designed to predict the impact of missense mutations in general. CONCLUSIONS/SIGNIFICANCE: Missense mutations are the most common disease-producing genetic variants. We present a fast, scalable bioinformatics method that integrates information about protein sequence, conservation, and structure in a likelihood ratio that can be integrated with medical genetics likelihood ratios. The protein likelihood ratio, together with medical genetics likelihood ratios, can be used by clinicians and counselors to communicate the relevance of a VUS to the individual who has that VUS. The approach described here is generalizable to regions of any tumor suppressor gene that have been structurally determined by X-ray crystallography or for which a protein homology model can be built.
format Text
id pubmed-2587343
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-25873432009-02-24 Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios Karchin, Rachel Agarwal, Mukesh Sali, Andrej Couch, Fergus Beattie, Mary S. Cancer Inform Original Research BACKGROUND: Missense (aminoacid changing) variants found in cancer predisposition genes often create difficulties when clinically interpreting genetic testing results. Although bioinformatics has developed approaches to predicting the impact of these variants, many of these approaches have not been readily applicable in the clinical setting. Bioinformatics approaches for predicting the impact of these variants have not yet found their footing in clinical practice because 1) interpreting the medical relevance of predictive scores is difficult; 2) the relationship between bioinformatics “predictors” (sequence conservation, protein structure) and cancer susceptibility is not understood. METHODOLOGY/PRINCIPAL FINDINGS: We present a computational method that produces a probabilistic likelihood ratio predictive of whether a missense variant impairs protein function. We apply the method to a tumor suppressor gene, BRCA2, whose loss of function is important to cancer susceptibility. Protein likelihood ratios are computed for 229 unclassified variants found in individuals from high-risk breast/ovarian cancer families. We map the variants onto a protein structure model, and suggest that a cluster of predicted deleterious variants in the BRCA2 OB1 domain may destabilize BRCA2 and a protein binding partner, the small acidic protein DSS1. We compare our predictions with variant “re-classifications” provided by Myriad Genetics, a biotechnology company that holds the patent on BRCA2 genetic testing in the U.S., and with classifications made by an established medical genetics model [1]. Our approach uses bioinformatics data that is independent of these genetics-based classifications and yet shows significant agreement with them. Preliminary results indicate that our method is less likely to make false positive errors than other bioinformatics methods, which were designed to predict the impact of missense mutations in general. CONCLUSIONS/SIGNIFICANCE: Missense mutations are the most common disease-producing genetic variants. We present a fast, scalable bioinformatics method that integrates information about protein sequence, conservation, and structure in a likelihood ratio that can be integrated with medical genetics likelihood ratios. The protein likelihood ratio, together with medical genetics likelihood ratios, can be used by clinicians and counselors to communicate the relevance of a VUS to the individual who has that VUS. The approach described here is generalizable to regions of any tumor suppressor gene that have been structurally determined by X-ray crystallography or for which a protein homology model can be built. Libertas Academica 2008-04-18 /pmc/articles/PMC2587343/ /pubmed/19043619 Text en © 2008 by the authors http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Original Research
Karchin, Rachel
Agarwal, Mukesh
Sali, Andrej
Couch, Fergus
Beattie, Mary S.
Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title_full Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title_fullStr Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title_full_unstemmed Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title_short Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios
title_sort classifying variants of undetermined significance in brca2 with protein likelihood ratios
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587343/
https://www.ncbi.nlm.nih.gov/pubmed/19043619
work_keys_str_mv AT karchinrachel classifyingvariantsofundeterminedsignificanceinbrca2withproteinlikelihoodratios
AT agarwalmukesh classifyingvariantsofundeterminedsignificanceinbrca2withproteinlikelihoodratios
AT saliandrej classifyingvariantsofundeterminedsignificanceinbrca2withproteinlikelihoodratios
AT couchfergus classifyingvariantsofundeterminedsignificanceinbrca2withproteinlikelihoodratios
AT beattiemarys classifyingvariantsofundeterminedsignificanceinbrca2withproteinlikelihoodratios